VWS_Headerbild_02_arrow

WELCOME

The Swiss Federal Foundation for Promotion of the National Economy through Scientific Research financially supports and furthers the founding of Swiss technology start-ups. Read more ›

VWS_Headerbild_03_arrow
VWS_Headerbild_01_arrow

Successes of the Foundation

Until 1995, the foundation supported basic research projects in Swiss universities that had the potential for economic impact if commercialized. Due to the challenging economic situation in Switzerland, as well as the almost nonexistent culture of supporting and developing young entrepreneurs, the foundation decided to redirect its efforts and attention to helping young entrepreneurs with their start-up endeavors. The effect and influence of our foundation was documented in the thesis of Mr. Markus Nieth at the institute for management studies of the Swiss Federal Institute of Technology, Zurich.

Businesses that received funding are required to document their progress in the Swiss Start-up Monitor, through which the foundation can monitor the success of the businesses that received funding.

The following businesses have received funding in the form of an interest free loan from our foundation:

Summer assessment 2017

Certus Diagnostics AG, 3052 Zollikofen
Certus Molecular Diagnostics AG develops, produces and distributes various diagnostic tests for the reliable, specific and cost effective Point-of-Care detection of infectious microorganisms. The novel technology can be used to identify the influenza virus, pneumonia-causing bacteria, the Zika virus and other microbes causing infections in humans and animals, or contaminations of food, water and medical products.
Loan CHF 100’000.-

MicroGauge AG, 8092 Zürich
MicroGauge is a newly founded ETH spin-off enabling next‐generation pressure sensing solutions for industrial vacuum systems. These vacuum systems include but are not limited to coating systems for medical implants and machining tools, optical and decorative glass coatings, as well as active layers in solar cells and OLED displays. Growing product complexity, as well as yield and reliability requirements demand precise and repeatable process control during material deposition. The process pressure is a crucial control parameter affecting the properties and quality of the deposited materials as well as the achieved manufacturing yield. The developed MicroGauge sensor utilizes MEMS (micro electro mechanical systems) technology and covers the entire vacuum pressure range of industrial coating machines. The inherent properties of the sensor measurement principle ensure a robust and reliable operation with high measurement accuracy and repeatability. A novel packaging approach drastically reduces drift and ensures long term stability.
Loan CHF 100’000.-

Vigilitech AG, 9410 Heiden
Vigilitech is a technology-based company whose main activities are in the field of monitoring vital physiological animal parameters with innovative technologies. There is no product on the market that combines simple and safe monitoring of heart rate, respiration rate and temperature for small animals in research (mice, birds, rats, etc.). Vigilitech invented MARTA (Monitoring Animals in Research with Technology and Application) which is a first product to assist researchers during surgical interventions on small fur- and feather-bearing animals.
MARTA consists of a simple innovative pad that enables heart rate and respiration rate measurements contact independently. Heart rate, respiration rate and temperature are visualized, and notes and pictures can be added on the mobile application.
MARTA streamlines the process of animal monitoring, data acquisition and data analysis to ensure transparent and high quality research. MARTA is fully in line with the 3R concept (replace, reduce and refine), animal welfare guidelines and GLP (good laboratory practice) standards.
Loan CHF 100’000.-

Dicronis, 8093 Zürich
Dicronis is developing a painless, user-friendly and reliable diagnostic system for accurately monitoring the lymphatic function in humans. The system is based on a patented, highly scalable microneedles platform technology developed at ETH Zurich. An FDA-approved fluorescent agent with an extremely high safety profile, integrated in polymeric dissolving microneedles patches can be delivered in a painless and minimally-invasive fashion. Through optically measuring the fluorescence decrease from the injection site, the status of the lymphatic system can be determined.
Loan CHF 100’000.-

Winter assessment 2016

Vibwife GmbH, 2560 Nidau
Vibwife has developed the world’s first active mobilizing system for aiding births. The system actively mobilizes the birthing mother thereby supporting the natural birth process of her child. The movements emulate what midwives do today the support a mother while giving birth. It is the goal to reduce the number of unplanned caesarian sections due to complications and also to reduce the time required to give birth.
Loan CHF 100’000.-, signing of contract 21.1.2017.

CyanoGuard AG, 8952 Schlieren
CyanoGuard AG is a spin-off of the University of Zurich. It has developed a rapid, easy to use and safe detection technology for toxins in liquid samples, specifically for cyanide. The technology combines efficient and easy-to-use indicators for toxins with solid-phase extraction. The company offers compact test kits to detect toxic and harmful substances in waste products of the mining and chemical industry, in food and in blood. Use in remote areas is possible. The technology delivers immediate results on the spot, without the need for expensive instrumentation, extensive training or time. The goal is to improve food safety, environmental monitoring and emergency healthcare. Key advantages over existing technology are high speed, selectivity, and safety with minimal requirements for training and equipment.
Loan CHF 100’000.-, signing of contract 16.12.2016.

Teleport SA, 1005 Lausanne
Video is the most-created, most-consumed medium on-line. However, currently the user experience is on a par with that of a DVD. This is a problem for engagement of the user in our age of extreme multitasking and shortened attention spans. Teleport offers a new interaction paradigm: it enables navigating freely in a video, by scrolling or jumping to any point. Contextual contents can be integrated in the image: texts, social media statuses, videos, can be used to give context. This allows an intuitive and immersive navigation, where the end-user can choose his level of engagement from a very cursory scan to in-depth exploration of the image and its explanations. The CMS allows the creation and administration of new applications by non-technical content publishers, through a web interface. Teleport targets all segments of non-linear video: education, product presentation, virtual tours, among others: categories where different users want to consume the content at a different pace or focus on different aspects.
Loan CHF 100’000.-, signing of contract 16.12.2016.

Intento SA, 1024 Ecublens
Intento SA is an EPFL spin-off developing a medical device for the rehabilitation of arm and hand of paralyzed stroke patients. 30% of overall stroke cases results in a severe paralysis of one half of the body. To date there are no effective solutions to treat severely paralyzed stroke patients. Stroke is increasingly affecting the younger population and there is a pressing need to effectively rehabilitate the younger individuals. Intento SA intends to provide to hospitals and rehabilitation centers an effective, evidence-based system to treat upper limb paralysis. Intento SA has developed a functional prototype and tested it in a proof-of-concept clinical study. The results achieved in producing functional recovery in severely paralyzed patients are currently unmatched by any other device or technology. In collaboration with the hospital of Lausanne, Intento SA showed in a clinical study that 80% of severely paralyzed patients displayed a clinically significant recovery, after only two weeks of usage, as opposed to conventional therapy that produced a relevant recovery in only 30% of the patients.
Loan CHF 100’000.-, signing of contract 16.12.2016.

Summer assessment 2016

Pregnolia AG, 8092 Zürich
Pregnolia has carried out biomechanical, engineering and clinical research efforts on the topic of cervical stiffness and its impact on preterm birth. As a clinical stage medical device company, pregnolia focuses on the development and commercialization of a diagnostic device for preterm birth. This medical device is capable of early identification of women in risk delivering preterm with significantly higher sensitivity than any other method currently available.
Loan CHF 100’000.-, signing of contract 22.7.2016.

Inositec AG, 8093 Zürich
Inositec is active in the field of engineering of small molecules and is a biotech spin-off from ETH Zurich developing innovative new drugs from its proprietary platform of inositol phosphate analogs with tunable properties (InosituneTM). Inositec targets billion-dollar markets with the aim of bringing life-saving therapies to patients.
Loan CHF 100’000.-, signing of contract 22.7.2016 (Loan was not utilized).

Winter assesement 2015

Bitsplitters GmbH, 8600 Dübendorf
Bitsplitters’ goal is to help people deal with the health-related effects of the sun through technology and knowledge. Bitsplitters plans to offer UV sensing systems that help people to decrease their risk of skin cancer and increase the general awareness of the effects of sunlight. To this end, Bitsplitters has created the cover brand «Sunbeat», for their UV sensing technology and respective consumer products. The constant improvement of the proprietary hard- and software, lead to UV sensing devices that are the smallest and most precise UV sensing devices on the market. They are small enough to be easily integrated into clothes and everyday objects, such as sunglasses or backpacks. The basic technology for the personal UV sensing systems was developed during a research project at ETH Zurich and continued by Bitsplitters.
Loan CHF 70’000.- No contract signed (Loan was not utilized).

IRsweep GmbH, 8093 Zurich
IRsweep develops next‐generation optical spectroscopy systems for chemical analysis. IRsweep’s vision is to revolutionize optical sensing by introducing quantum cascade laser frequency comb spectroscopy. Dual comb spectroscopy radically reformed traditional Fourier transform spectroscopy in the near-infrared. IRsweep extends this innovative solution to the mid-IR spectral range, the sweet spot for highly sensitive spectrometers. As the technology readiness increases, IRsweep will first provide a laboratory instrument and then integrate the system further to target industrial on‐line applications. Key advantages over existing equipment are high speed, selectivity, and sensitivity at low maintenance, which will propel industrial adoption. The disruptive technology will lead to intelligent and highly accurate sensors for industrial, medical, and security applications. These sensors will help to reduce the emission of toxic gases, monitor effectiveness of processes in real time and increase the yield and the efficiency of today’s industry. Using a proof‐of‐principle setup in the laboratories at ETH Zurich, the suitability for spectroscopy was recently demonstrated. IRsweep was founded to commercialize this disruptive new optical sensing approach.
Loan CHF 100’000.- signing of contract 12.1.2016.

Dermolockin GmbH, 8401 Winterthur
Skin cancer has become a major health issue in industrialized countries in recent years. The current diagnosis of skin cancer relies on the visual examination of the lesion, which is problematic since some lesions do not exhibit clear margins and information about the invasion depth is not available. The Dermolockin approach is based on lock-in thermal imaging, a proven technique for the non-destructive testing of surfaces, capable of detecting very small variations of the thermal properties. Using this technology, the Dermolockin device offers an objective and reliable, but non-invasive, diagnostics of suspicious lesions. Its imaging capabilities, allow the precise determination of margins and the depth of the skin lesions. The goal of the company is to offer a reliable method that will allow dermatologists to detect both the margins and the penetration depth of skin lesions with high accuracy. Dermolockin GmbH is a recently founded spin-off from the Zurich University of Applied Sciences (ZHAW) located in Winterthur.
Loan CHF 100’000.- signing of contract 28.12.2015.

Lucentix SA, 1110 Morges
Lucentix SA develops a novel biosensor technology that will allow patients to measure the precise amounts of diverse substances in their blood using a device that is as simple as the blood glucose meter for diabetics. It is conceptually different from existing approaches in that it will enable patients to measure precise concentrations of biomarkers and drugs anytime and anywhere. The Lucentix SA technology represents a technological breakthrough for the treatment of various intractable medical conditions. Lucentix SA will commercialize this technology and develop a simple diagnostics device that can reliably measure the concentration of a biomarker or drug from a single drop of blood or saliva. Envisioned is a handheld diagnostics device that provides precise results, which can be used immediately by the patient to adjust the treatment, or the results, can be e-mailed to the treating doctor for further analysis. Similar to glucose meters that employed by patients to self-manage their diabetes, this new device would deliver laboratory-quality results in minutes and at the point-of-care. The technology was invented at EPFL by the three founders, and is protected by three PCT patent applications.
Loan CHF 100’000.- signing of contract 28.12.2015.

Summer assessment 2015

Cellestia Biotech S.A., 1015 Lausanne
Cellestia Biotech S.A. is a Swiss start-up spun-out of EPFL, established in May 2014, and located at the EPFL campus, Lausanne. Cellestia Biotech is engaged in the development of novel mechanism based targeted therapeutics to address unmet medical needs, with an emphasis on oncology. Specifically, Cellestia Biotech is developing unique therapeutics to treat Notch driven human cancers such as Triple negative breast cancer, Chronic lymphocytic leukemia and T-cell lymphocytic leukemia. Cellestia’s pipeline includes three innovative first-in-class programs and one drug-repositioning program for oncology indications. In addition, Cellestia’s drug development program is complemented by a companion biomarker assay, thereby allowing patient stratification during clinical phases of development.
Amount of funding CHF 30’000.-, signing of contact 10.8.2015 (Loan repaid).

Winter assessment 2014

rqmicro GmbH, 8093 Zurich
rqmicro provides a novel system for the rapid detection of water and food pathogens. These pathogenic organisms lead to human disease, kill millions of people each year and cause economic damages in the billions. The main USPs of rqmicro technology are an enhanced sensitivity with higher accuracy and lower detection limits and a time‐to‐result of less than 1 hour compared to days to weeks for today’s gold‐standard, cultivation‐dependent methods. This is achieved through the intelligent synthesis of an enrichment technology (immunomagnetic separation, IMS), a proprietary microfluidic lab‐on‐a‐chip technology and high‐speed single‐cell counting (flow cytometry, FCM).
Amount of funding CHF 100’000.-, signing of contact 23.4.2015.

IONight AG, 3004 Bern
The company IONIGHT AG is a spin-off of the University of Bern aiming at producing leading edge Laser Ablation Ionization Mass Spectrometers (LIMS) designed for laboratory and field applications, building on the technology designed and developed for in-situ exploration of our solar system. IONIGHT currently offers on the market a sample analysis service (SLMS™) and research instrument (R-LMS™). The product line will be extended in the next two years with a laboratory instrument (L-LMS™) for daily routine analyses and a portable instrument (FLMS™) for field applications.
Amount of funding CHF 100’000.-, signing of contact 25.2.2015.

Summer assessment 2014

Versantis, 8093 Zurich
Is developing a highly innovative dialysis technology capable of removing diverse harmful compounds from an intoxicated patient. The novel versatile antidote approach is capable of rapidly removing a variety of toxic agents from the organism to save patients from metabolic and drug overdoses. Versantis will answer crucial medical needs in the support of neonates with congenital metabolic disorders, and patients suffering from cirrhosis, hepatic failure, or overdose from prescription and illicit drugs.
Amount of funding CHF 100’000.-, signing of contact 9.4.2015 (Loan repaid).

Mimedis AG, 4057 Basel
Provides implant design software to surgeons considering given anatomical guidelines. With the design template from the surgeon, MIMEDIS produces and delivers personalized bone implants within a few working days through highly flexible production processes using 3D Printing.
Amount of funding CHF 100’000.-, signing of contract 18.08.2014. (Loan was not utilized)

CodeTickler, 1015 Lausanne
Develops deep program-binary analysis that helps organizations and consumers secure their IT assets with an automated defense system that finds vulnerabilities in software, and then shields these vulnerabilities against exploits and malware.
Amount of funding CHF 100’000.-, signing of contact 2.12.2014. (Loan repaid)

Calcisco AG, 3012 Bern
Develops and commercializes the very first and only diagnostic blood test available for the determination of calcification risk/propensity in serum (T50 test). The main product will be a diagnostic test kit sold and distributed to clinical laboratories. The first target group to benefit from the test will be chronic kidney disease (CKD) patients. First a research test service will be launched, the diagnostic test kit will follow. Extension to the general cardiovascular field is envisaged and novel treatment options to reduce calcification risk will be developed.
Amount of funding CHF 100’000.-, signing of contract 30.09.2014. (Loan was not utilized)

Winter assessment 2013

One Drop Diagnostics AG, 2000 Neuchâtel
Develops point-of-care diagnostics devices. Have developed a handheld device that provides rapid, accurate and sensitive diagnostics of multiple proteins from one drop of blood. Has potential to revolutionize medical diagnostics by allowing anyone to perform laboratory quality blood tests anywhere. Aims to be an original equipment manufacturer (OEM) to established diagnostics and pharmaceutical companies with high market penetration and widespread distribution network.
Amount of funding CHF 100’000.-, signing of contract 18.12.2013.

Summer assessment 2013

LESS SA, 1015 Lausanne
Aims at developing, manufacturing and marketing low power consumption backlighting units that emit more light and less local heat. This potentially increases either the battery life or allows the use of faster processors on the same battery possible. Traditional mid-sized displays as found in tablets (e.g. iPad) and notebooks are backlit with white-light LEDs that emit a significant amount of heat in addition to light. In addition to displays, the systems can be used in multiple applications that need a high degree of light uniformity in a compact form, e.g., in the inspection lighting areas.
Amount of funding CHF 100’000.-, signing of contract 05.08.2013. (Loan repaid)

Amal Therapeutics SA, 1227 Geneva
The goal of the company is to develop and progress a new generation of therapeutic cancer vaccines into clinical trials. We have developed a unique approach combining an optimal and proprietary vector composed of a cell penetrating peptide linked to a multi–‐epitopic antigenic cargo. This innovative approach can be seen as a platform that can be developed for any cancer indication. The first indication targeted is primary brain tumors.
Amount of funding CHF 100’000.-, signing of contract 05.08.2013. (Loan repaid)

3db Access AG, 8800 Thalwil
Die 3db Technologies AG hat zum Ziel einen Mikrochip auf den Markt zu bringen, der es erlaubt, Distanzen in einer sicheren Art und Weise zu messen, um bei sensitiven Anwendungen wie Zugangssystemen oder Mobile Payment-Systemen Sicherheitslücken bestehender Systeme zu beheben und Missbrauch zu verhindern.
Amount of funding CHF 100’000.-, signing of contract 18.11.2013. (Loan repaid)

Winter assessment 2012

Phocone AG, (today Camlin Technologies Switzerland AG), 8005 Zurich
Develops, produces and sells novel mid-infrared laser modules well suited for gas detection, particularly of flammable hydrocarbons. The technology allows the detection of many gases, in a fast and precise way.
Amount of funding CHF 100’000.-, signing of contract 10.12.2012 (Loan was not utilized)

DynaDes AG, 8057 Zurich
Development and licensing of highly specific Kinase-Inhibitors, which protect against diseases through a highly developed, IP protected molecular design platform.
Amount of funding CHF 125’000.-, signing of contract 23.04.2013. (Loan repaid)

Summer assessment 2012

UrbanFarmers AG, 8005 Zurich
Development, production, operation and trading of and with systems and apparatus for food production, administration of usage and production rights, production and trading of and with foods. Furthermore this company offers architectural, planning, development and support services for applications in an urban agriculture. This company develops visionary concepts for urban agriculture with regards to economical, ecological and social values.
Amount of funding CHF 100’000.-, signing of contract 14.11.2012.

Mabimmune Diagnostic AG, 8952 Schlieren
This company develops methods of diagnostics including diagnostic imaging. This company also does research, develops therapies and prevention on and of human diseases. Furthermore this company issues the development and selling of diagnosis and pharmaceutical products and their required licenses.
Amount of funding CHF 100’000.-, signing of contract 17.08.2012 (Loan repaid).

Mirasense AG, 8037 Zurich
Development, operation and sales of software solutions related to mobile and other electrical devices. Furthermore consulting, planning and executing EDV-Applications. Trading with goods of all kinds, especially software and electronic devices.
Amount of funding CHF 100’000.-, Loan was not used up until August 2012. Due to special circumstances the loan was awarded a second time on the 29.08.2012 (Loan repaid).

Winter assessment 2011

Uepaa AG, 8005 Zurich
Development, production and marketing of smartphone technology with a focus on tracking, alerts and rescue (TAR).
Amount of funding CHF 100’000.-, signing of contract 18.04.2012 (Loan repaid).

Skope Magnetic Resonance Technologies GmbH, 8092 Zurich
Development, production, trading and sales of and with electrical and medical devices and products including the required soft and hardware and all relevant services. Acquisition and administration of intellectual property rights.
Amount of funding CHF 100’000.-, signing of contract 07.12.2011 (Loan repaid).

Summer assessment 2011

Winterthur Instruments GmbH, 8405 Winterthur
Development, production and sales of systems for assessing materials.
Amount of funding CHF 100’000.-, signing of contract 20.07.2011 (Loan repaid).

Ability AG (Formerly Habtronics GmbH) , 8052 Zurich
Development and production of training apparatuses with a focus on rehabilitation.
Amount of funding CHF 100’000.-, signing of contract 08.08.2011.

Aeon Scientific AG, 8092 Zurich
Development and production of electromagnetic systems for manipulation on the micro level with a focus on biomedical applications.
Amount of funding CHF 100’000.-, signing of contract 20.07.2011 (Loan repaid).

Kandou Technologies SA, 1015 Lausanne
Development, licensing and sales of permanent technological interfaces between electronic components.
Amount of funding CHF 100’000.-, signing of contract 28.07.2011 (Loan repaid).

Winter assessment 2010

Climeworks AG, 8044 Zurich
Development, production, sales and operation of systems or their components that filter the carbon dioxide out of atmospheric air or exhausted air and are able to save, store and recycle the carbon dioxide.
Amount of funding CHF 105’000.-, signing of contract 31.01.2011 (Loan was not utilized).

Summer assessment 2010

Nanotion AG, 8005 Zurich
Development, production and sales of analysis devices for verifying nanoparticles in liquids, the corresponding software, other devices and services related to those products.
Amount of funding CHF 100’000.-, signing of contract 05.08.2010 (Loan repaid).

YouRehab Ltd., 8001 Zurich
Development, production, storage, sales and trading with and of medical devices. Furthermore this company powers the development of the corresponding software, offers consulting services and does trading with hard and software.
Amount of funding CHF 105’000.-, signing of contract 23.08.2010 (Loan written off).

Winter assessment 2009

InSphero AG, 8051 Zurich
Research, development, production and sales of systems and supplies for producing biological tissue.
Amount of funding CHF 100’000.-, signing of contract 26.01.2010. (Loan repaid)

Mirasense AG, 8037 Zurich
Development, operation and sales of software solutions relating to mobile and other electrical devices. Furthermore consulting, planning and executing EDV-Applications. Trading with goods of all kinds, especially software and electronic devices.
Amount of funding CHF 100’000.-, signing of contract 06.08.2010 (Loan was not utilized).

Summer assessment 2009

greenTEG GmbH, 8003 Zurich
Development, production, sales and trading of thermo-electrical apparatuses and components.
Amount of funding CHF 100’000.-, signing of contract 29.09.2009 (Loan repaid).

Winter assessment 2008

Preclin Biosystems AG, 8952 Schlieren
Research, Development and sales of pharmaceuticals and services related to research and development of medical products.
Amount of funding CHF 100’000.-, signing of contract 18.01.2009 (Loan repaid).

Lemoptix SA, 1015 Lausanne
Development and commercialization of technologies, products and fabrication processes in the area of microsystem with a special focus on micro video projection.
Amount of funding CHF 100’000.-, signing of contract 19.01.2009 (Loan repaid).

Celeroton AG, 8092 Zurich
Development, production, trading and licensing in the area of electrically driven systems and mechatronics. Also offers services regarding electrically driven systems and mechatronics.
Amount of funding CHF 100’000.-, signing of contract 12.02.2009 (Loan repaid).

evalueScience AG, 8008 Zurich
Offers consulting services for science projects, business ideas, academic programs and cadre staff in research and education.
Amount of funding CHF 100’000.-, signing of contract 01.07.2009 (Loan repaid).

Summer assessment 2008

Optotune GmbH, 8600 Dübendorf
Development, production, sales and trading of and with adaptive material systems, focusing on optics.
Amount of funding CHF 100’000.-, signing of contract 14.08.2008 (Loan repaid).

Zurich Instruments AG, 8005 Zurich
Development, production and sales of electronic measuring devices and their necessary software.
Amount of funding CHF 100’000.-, signing of contract 26.08.2008 (Loan repaid).

Winter assessment 2007

NeMoDevices GmbH, 8802 Kilchberg
Development, production and sales of products for the medical market.
Amount of funding CHF 150’000.-, signing of contract 29.12.2007 (Loan repaid).

Summer assessment 2007

ChromaCon AG, 8093 Zurich
Development, production sales and licensing of engendered processes and assets. Also offers consulting for the above.
Amount of funding CHF 100’000.-, signing of contract 24.07.2007 (Loan repaid).

kooaba GmbH, 8038 Zurich
Offers new, image based services for mobile devices. Mobile phones being such an example.
Amount of funding CHF 100’000.-, signing of contract 23.07.2007 (Loan repaid).

Arktis Radiation Detectors AG, 8093 Zurich
Development, production sales and storage of radiation measurement and product investigation devices. Offers research and consulting services in the area of security, reduction of threat and radiation protection nationally and internationally.
Amount of funding CHF 100’000.-, signing of contract 17.12.2007 (Loan repaid).

Winter assessment 2006

Redbiotec AG, 8093 Zurich
Research, development, production and sales of products in the area of biotechnology, diagnostics and therapies. Also Purchases, uses and sells patients in that subject area.
Amount of funding CHF 100’000.-, signing of contract 11.02.2007 (Loan repaid).

Dectris AG, 5400 Baden
Development, production and trading of and with electronic measuring devices for scientific and industrial use. Purchase and marketing of intellectual property. Offers services and consulting to third parties.
Amount of funding CHF 100’000.-, signing of contract 12.02.2007 (Loan was not utilized).

LiberoVision AG, 8037 Zurich
Development, production and maintenance as well as sales and promotions of all kinds of soft and hardware. A special focus is given to the area of computerized visualization technology in context of generating, modifying, saving, compressing, transmitting and visualizing of real and/or virtual audio visuals and data streams.
Amount of funding CHF 100’000.-, signing of contract 24.02.2007 (Loan repaid).

Gatlik GmbH, 4056 Basel
Trading of goods. Production of systems including end user software for research and development and industrial production. Offers services for research and development as well as finance and planning with a strong focus on investment strategies.
Amount of funding CHF 100’000.-, no contract was signed.

Summer assessment 2006

No proposals granted.

Winter assessment 2005

CovalX GmbH, 8046 Zurich
Research development, production and marketing of products in the area of health and biology with focus on analytics and diagnostics.
Amount of funding CHF 100’000.-, signing of contract 16.01.2006 (Loan repaid).

Summer assessment 2005

HeiQ Materials Ltd, 8005 Zurich
Production and trading of surface treatment materials, functioning additives, technical fibers, tissues, textiles and synthetics that possess antibiotic, cleaning, protective or performance-enhancing features.
Amount of funding CHF 100’000.-, signing of contract 04.08.2005 (Loan repaid).

Optical Additives GmbH, 3073 Gümligen
Invention, development, production, marketing and sales of materials, methods, and services in the subject areas of ophthalmology, optics, optical devices and aids, organic and non-organic glass and surface coatings.
Amount of funding CHF 100’000.-, signing of contract 01.06.2006 (Loan was not utilized).

Winter assessment 2004

No proposals granted.

Summer assessment 2004

PhotoDerma SA, 1018 Lausanne
Research, development and commercialization in and of therapeutic, cosmetic and diagnostic products and technical devices for curing and diagnosing focusing on dermatology.
Amount of funding CHF 80’000.-, runtime 24 months, signing of contract 29.07.2004 (Loan repaid).

GlycoVaxyn AG, 8008 Zurich
Provision of services through chemical, physical, microbiological and molecular biological methods. Development of methods and products for animal, human and aliment medicine.
Amount of funding CHF 100’000.-, runtime 24 months, signing of contract 13.07.2005 (Loan repaid).

Winter assessment 2003

Timaq Medical Imaging AG, 8006 Zurich
Active in the area of medical related imaging, including the capturing and assessing of clinical experiments.
Amount of funding CHF 100’000.-, runtime 24 months, signing of contract 27.02.2004 (Loan partly repaid, partly written off).

Summer assessment 2003

Spectraseis GmbH, 8702 Zollikon
Services and consulting in the oil and gas industry.
Amount of funding CHF 100’000.-, runtime 24 months, signing of contract 29.08.2003 (Loan repaid).

Cistronics Cell Technology GmbH, 8093 Zurich
Research, development, production, and marketing of antibacterial products as well as services regarding the above.
Amount of funding CHF 100’000.-, runtime 24 months, signing of contract 19.12.2003 (Loan was never utilized).

Winter assessment 2002

Concentris GmbH, 4055 Basel
Services and production in the area of computer science and technology with special regards to the use of internet and intranet through applications or database technologies.
Amount of funding CHF 93’000.-, runtime 2 years, signing of contract 23.12.2002 (Loan repaid).

COVALYS Biosciences AG, 4132 Muttenz
Development, production and trading of and with products and materials used to do research on biological processes.
Amount of funding CHF 100’000.-, runtime 18 months, signing of contract 28.12.2002 (Loan repaid).

Summer assessment 2002

C-CIT AG, 8820 Wädenswil
Development and production of products that can identify biological and chemical substances. Product licensing for the selling at suitable distributers. Services regarding those kind of products.
Amount of funding CHF 113’000.-, runtime 1 years, signing of contract 19.08.2002.

Winter assessment 2001

CellnTech Advanced Cell Systems AG, 3012 Bern
Development and production as well as analysis and sales of cell cultures and other related products.
Amount of funding CHF 130’000.-, runtime 2 years, signing of contract 22.06.2002 (Loan repaid).

Lipideon Biotechnology AG, 8092 Zurich
Research and development as well as administration of medicine and nutraceuticals that are specifically designed to reduce the cholesterol level in the blood.
Amount of funding CHF 100’000.-, runtime 2 years, signing of contract 25.03.2002 (Loan repaid).

Summer assessment 2001

Millenium Biologix AG, 8952 Schlieren
Research, development, production and marketing of medicine related, biomedicine and biotechnology products as well as all services related to those products.
Amount of funding CHF 100’000.-, runtime 1 year, signing of contract 20.09.2001 contract extended to 31.12.2004 (Loan repaid).

Parabol Technologies S.A., 1007 Lausanne
Consulting and technical services in the area of micro technology and microsystems for research with specific focus on biological science of clinical diagnostics and other related areas.
Amount of funding CHF 100’000.-, runtime 1 year, signing of contract 27.09.2001 (Loan written off).

Winter assessment 2000

Neuronics AG, 8005 Zurich
Development and sales of Soft- and Hardware for the data transmission through neurological networks. Robotics and embedded systems of every kind. Also training and consulting.
Amount of funding CHF 120’000.-, runtime 2 years, signing of contract 01.03.2001 contract extended to the 30.06.2005 (Loan repaid).

Summer assessment 2000

MyoContract Ltd., 4056 Basel
Research in the area of remedies specifically for muscle related illnesses. In particular, muscular dystrophy. Administration of research results as well as production and sales of pharmaceutic products.
Amount of funding CHF 150’000.-, runtime 2 years, signing of contract 19.07.2000 (The loan was never used due to the quick finding of venture-capital because of the positive assessment by our foundation).

Summer assessment 1999

Thales Technologies AG, 8005 Zurich
Specialized services for analytics and diagnostics in the chemical industry and other related areas of research and development.
Amount of funding CHF 100’000.-, runtime 2 years, signing of contract 22.07.1999 (Loan repaid).

Winter assessment 1998

Sensorix AG, 8005 Zurich
Development, production, sales and services of and for special chemical and biological substances.
Amount of funding CHF 100’000.-, runtime 2 years, signing of contract 18.05.1999 (Loan repaid).

Summer assessment 1998

Alpha Sensors AG, (today Sensirion AG), 8093 Zurich
Development, production and sales of sensors and other technology products.
Amount of funding CHF 100’000.-, runtime 2 years, signing of contract 19.01.1999 (Loan was not utilized).

The Genetics Company, 8057 Zurich
Identification and characterization of drug targets and small molecule compounds through in-vivo models for drug development.
Amount of funding CHF 100’000.-, runtime 2 years, signing of contract 23.10.1998 (Loan repaid).

ESBATech AG, 8057 Zurich
Identification and optimization of substances that can subsequently be used in medical applications.
Amount of funding CHF 100’000.-, runtime 2 years, signing of contract 23.10.1998 (Loan repaid).

Winter assessment 1997

No proposals approved.

Summer assessment 1997

White Spot AG, 6342 Baar
Traumatology and osteosynthesis development business. Developed and commercialized the IGF-1 and the BMB-2. Made shock absorbable implants for the osteosynthesis waterproof.
Amount of funding CHF 150’000.-, runtime 3 years, signing of contract 24.03.1998 (Loan written off).

© 2016 Eidgenössische Stiftung zur Förderung schweizerischer Volkswirtschaft durch wissenschaftliche Forschung | Alle Rechte vorbehalten | Impressum